Colombia

In Colombia, health product regulation is overseen by INVIMA, which operates under the authority of the Ministerio de Salud y Protección Social. The primary legal framework is established by Decree 677 of 1995 for pharmaceuticals and Decree 4725 of 2005 for medical devices and diagnostics, with additional resolutions governing digital health tools and in vitro diagnostics. INVIMA is responsible for granting market authorizations (registros sanitarios), conducting post-market surveillance, and enforcing quality standards across all health product categories. The approval process generally involves a dossier submission reviewed by the corresponding INVIMA group (pharmaceuticals, medical devices, or food and beverages), followed by technical evaluation, potential requests for additional information, and issuance of a sanitary registration valid for ten years.

Applicants must appoint a legally recognized local representative (titular del registro sanitario) domiciled in Colombia, who assumes full regulatory responsibility for the product. INVIMA accepts dossiers aligned with the Common Technical Document (CTD) format for pharmaceuticals, and for medical devices, submissions must comply with the technical requirements outlined in Decree 4725 of 2005, which references international standards such as those from ISO and IMDRF. Colombia is an active member of the Pan American Network for Drug Regulatory Harmonization (PANDRH) and has progressively adopted harmonized guidelines. Recent reforms include the implementation of INVIMA's digital submission platform (SIAP), streamlined expedited pathways for innovative and priority medicines under Resolution 330 of 2017, and ongoing efforts to align with international regulatory convergence initiatives, including recognition of approvals from reference regulatory authorities (EMA, FDA, Health Canada) to potentially accelerate local review timelines.

Public procurement of health products in Colombia is primarily coordinated through the Ministerio de Salud y Protección Social and executed by Entidades Promotoras de Salud (EPS) and Instituciones Prestadoras de Salud (IPS) within the framework of the Sistema General de Seguridad Social en Salud (SGSSS). The national body Colombia Compra Eficiente governs public purchasing rules under Law 1150 of 2007 and its subsequent decrees, mandating transparent tender processes through the SECOP (Sistema Electrónico de Contratación Pública) platform. The Fondo Colombiano de Enfermedades de Alto Costo (CAC) and the Ministerio de Salud centralize procurement for high-cost medicines and technologies, including those covered under the Plan de Beneficios en Salud (PBS). Price controls for medicines are regulated by the Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos (CNPMDM), which applies reference pricing and freedom-of-price or direct control regimes depending on product classification.

The private sector represents a significant procurement channel in Colombia, with private clinics, pharmacy chains, and hospital networks purchasing directly from distributors and manufacturers, often through negotiated contracts outside public tender frameworks. International donor and multilateral procurement plays a more limited role compared to lower-income regional markets; however, agencies such as PAHO/WHO, UNICEF, and the Global Fund do support specific public health programs, particularly for HIV/AIDS, tuberculosis, and malaria commodities. USAID and other bilateral donors periodically fund health product procurement through targeted programs. Colombia does not currently enforce explicit domestic manufacturing preference policies in public tenders, but the government has expressed strategic interest in strengthening local pharmaceutical production capacity, and policy discussions around promoting national industry are ongoing within the broader health technology and industrial policy agenda.